ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 612. Collins SP, Pang PS, Fonarow GC, Yancy CW, Bonow RO, Gheorghiade M. Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol. 2013;61(2):121-6. 613. ZuckermanRB,SheingoldSH,OravEJ,RuhterJ,EpsteinAM.Readmissions, observation, and the hospital readmissions reduction program. N Engl J Med. 2016;374(16):1543-51. 614. Collins SP, Schauer DP, Gupta A, Brunner H, Storrow AB, Eckman MH. Cost-effectiveness analysis of ED decision making in patients with non- high-risk heart failure. Am J Emerg Med. 2009;27(3):293-302. 615. Collins SP, StorrowAB. Acute heart failure risk stratification: canwe define low risk? Heart Fail Clin. 2009;5(1):75-83, vii. 616. Peacock WF. Using the emergency department clinical decision unit for acute decompensated heart failure. Cardiol Clin. 2005;23(4):569-88, viii. 617. Butler J, Hanumanthu S, Chomsky D, Wilson JR. Frequency of low-risk hospital admissions for heart failure. Am J Cardiol. 1998;81(1):41-4 618. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling pressures in patients with and without congestive heart failure. Chest. 2001;120(2):467-73. 619. Masip J, Gayà M, Páez J, Betbesé A, Vecilla F, Manresa R, et al. Pulse oximetry in the diagnosis of acute heart failure. Rev Esp Cardiol (Engl Ed). 2012;65(10):879-84. 620. Branson RD, Johannigman JA. Pre-hospital oxygen therapy. Respir Care. 2013;58(1):86-97. 621. Masip J, Roque M, Sánchez B, Fernández R, Subirana M, Expósito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005;294(24):3124-30. 622. Chen Y, Chen P, Hanaoka M, Huang X, Droma Y, Kubo K. Mechanical ventilation in patients with hypoxemia due to refractory heart failure. Intern Med. 2008;47(5):367-73. 623. Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD. Effect of non-invasive positive pressure ventilation (NIPPV) onmortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet. 2006;367(9517):1155-63. 624. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J; 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-51. 625. Sacchetti A, Ramoska E, Moakes ME, McDermott P, Moyer V. Effect of ED management on ICU use in acute pulmonary edema. Am J Emerg Med. 1999;17(6):571-4. 626. Miró Ò, Hazlitt M, Escalada X, Llorens P, Gil V, Martín-Sánchez FJ, et al; ICA-SEMES Research Group. Effects of the intensity of prehospital treatment on short-term outcomes in patients with acute heart failure: the SEMICA-2 study. Clin Res Cardiol. 2018;107(4):347-61. 627. Testani JM,Chen J,McCauleyBD,KimmelSE,ShannonRP.Potentialeffects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265-72. 628. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail. 2010;16(7):541-7. 629. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interactionwith renal function. Circ Heart Fail. 2012;5(1):54-62. 630. Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964-75. 631. Di Lullo L, Bellasi A, Russo D, Cozzolino M, Ronco C. Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment. Int J Cardiol. 2017 Jan 15;227:143-50. 632. Martens P, Nijst P, Mullens W. Current approach to decongestive therapy in acute heart failure. Curr Heart Fail Rep. 2015;12(6):367-78. 633. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, et al. Decongestion in acute heart failure. Eur J Heart Fail. 2014;16(5):471-82. 634. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. [2016 ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure]. Kardiol Pol. 2016;74(10):1037-147. 635. Ho EC, Parker JD, Austin PC, Tu JV, Wang X, Lee DS. Impact of nitrate use on survival in acute heart failure: a propensity-matched analysis. J Am Heart Assoc. 2016 Feb 12;5(2). pii: e002531. 636. Singh A, Laribi S, Teerlink JR, Mebazaa A. Agents with vasodilator properties in acute heart failure. Eur Heart J. 2017;38(5):317-25. 637. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013 Aug 6(8):CD005151. 638. Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med. 2008;36(1 Suppl):S106-11. 639. Cody RJ. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction. J Am Coll Cardiol. 1988;12(2):559-61. 640. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4(4):515-29. 641. Unverferth DA, BlanfordM, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med. 1980;69(2):262-6. 642. Montera MW, Pereira SB, Colafranceschi AS, Almeida DR, Tinoco EM, Rocha RM, et al. Summary of the II Brazilian Guideline update on Acute Heart Failure 2009/2011. Arq Bras Cardiol. 2012;98(5):375-83. 643. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al; OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from theOPTIME-CHF study. J Am Coll Cardiol. 2003;41(6):997-1003. 644. ChioncelO,MebazaaA,HarjolaVP,CoatsAJ,PiepoliMF,Crespo-LeiroMG, etal;ESCHeartFailureLong-TermRegistryInvestigators.Clinicalphenotypes and outcome of patients hospitalized for acute heart failure: the ESCHeart Failure Long-TermRegistry. Eur J Heart Fail. 2017;19(10):1242-54. 645. PackerM. REVIVE II:Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation. 2005;112:3362-4. 646.ElkayamU,TasissaG,BinanayC,StevensonLW,GheorghiadeM,WarnicaJW, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. AmHeart J. 2007;153(1):98-104. 647. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, andmilrinone in themanagement of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):47G-58G. 648. Campia U, Nodari S, GheorghiadeM. Acute heart failure with low cardiac output: canwe develop a short-term inotropic agent that does not increase adverse events? Curr Heart Fail Rep. 2010;7(3):100-9. 649. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46(1):57-64. 650. GheorghiadeM, AbrahamWT, Albert NM, Greenberg BH, O'Connor CM, She L, et al; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296(18):2217-26. 535